Table 1.

Primers sequence.

Targeted gene	Direction and Sequence
NF-κB p65	F: 5′-CTGCCGAGTAAACCGGAACT-3′	R: 5′-CCCTGTGACATCACCTGCTT-3′
IκBα	F: 5′-AAGGCTACTCCCCCTACCAG-3′	R: 5′-CAAGAAGGCGACACAGACCT -3′
GM-CSF	F: 5′-AGCTTTACGAGAGCTCTTTTGC-3′	R: 5′-CACATCCTCCTCAGGACCTT-3′
iNOS	F: 5′-TCAGCCAAGCACTCCAATGT-3′	R: 5′-AGTGATGGAGGTGCCCTAGT-3′
MCP-1	F: 5′-CAAAGCCAGGGGCCTTTTTC-3′	R: 5′-TACCAGGAGCCAGGCATAGT-3′
TNF-α	F: 5′-GGACTAGCCAGGAGGGAGAA-3′	R: 5′-CGCGGATCATGCTTTCTGTG-3′
IL-6	F: 5′-GCCTTCTTGGGACTGATGCT-3′	R: 5′-GACAGGTCTGTTGGGAGTGG-3′
GAPDH	F: 5′-GTCAAGGCCGAGAATGGGAA-3′	R: 5′-CTCGTGGTTCACACCCATCA-3′

NF-κB p65, Nuclear factor kappa B; IκBα, Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; GM-CSF, Granulocyte-macrophage colony-stimulating factor; iNOS, Inducible nitric oxide synthase; MCP-1, Monocyte Chemoattractant Protein-1; TNFα, Tumour necrosis factor α; IL-6, Interleukin 6; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.